Biotech Values

[DewDiligence]

ARLZ +11% on acquisition of US rights to AZN’s Toprol XL:

http://finance.yahoo.com/news/aralez-acquire-astrazeneca-u-rights-060500998.html

The agreement includes an initial upfront payment of $175 million , which will be financed through a previously committed senior secured debt facility with Deerfield Management.

ARLZ’s business plan appears to include picking up unwanted assets from Big Pharma—see Zontivity deal (#msg-125008718).